相关实验视频

Updated: May 5, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

具有潜在抗癌活性的新型库马林-核基混合体:合成,基于体外细胞的评估和分子对接

Maiara Correa de Moraes^1,2, Rafaele Frassini³, Mariana Roesch-Ely³

¹Laboratório de Biotecnologia de Produtos Naturais e Sintéticos, Universidade de Caxias do Sul, Francisco Getúlio Vargas St., 1130, Caxias do Sul 95070-560, RS, Brazil.

Pharmaceuticals (Basel, Switzerland)

|July 27, 2024

概括

通过结合自然分子开发了新的抗癌药物候选药物. 化合物9a对预测毒性低的结肠癌细胞表现出显著的活性,这表明了一种有前途的新疗法方法.

科学领域:

药用化学医学化学
有机合成有机合成
药理学药理学是指药理学的学科.

背景情况:

核基和氨酸等自然产品是生物活性化合物的来源.
分子杂交是一种创建具有增强性质的新分子的策略.
抗癌药物的发现需要识别具有强效和低毒性的化合物.

研究的目的:

为了合成和评估从核基 (乌拉,胺) 或神和氨酸中提取的新型混合化合物.
评估这些化合物的体外抗癌活性与人类瘤细胞系.
研究合成化合物的潜在药理标和毒性概况.

主要方法:

通过1,2,3-三醇异环连接的混合化合物的合成.
在体外对结肠癌 (HCT116),喉瘤 (Hep-2) 和肺癌 (A549) 细胞系进行抗癌活性测试.
在的分子对接研究和毒性预测.

主要成果:

化合物9a对HCT116细胞表现出显著的抗癌活性 (IC50 = 24.19 ± 1.39 μM),选择性指数为6.
分子对接表明对Topoisomerase 1-DNA复合物的高度亲和力,表明一种潜在的作用机制.
在的毒性预测表明,原和瘤效应的风险较低.

结论:

自然衍生物的分子杂交是一种可行的策略,用于发现新的抗癌药物.
化合物9a是作为抗癌药物进一步开发的有希望的候选药物.
合成的化合物显示出有针对性癌症治疗的潜力,具有有利的安全性.

关键词:

这是一种抗癌药物.库马林是一种素.分子对接的分子对接.分子混合化分子混合化.核基是核基的组成部分.

更多相关视频

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...